Quest PharmaTech Inc. (CVE:QPT – Get Free Report) shares reached a new 52-week low during mid-day trading on Tuesday. The stock traded as low as C$0.02 and last traded at C$0.02, with a volume of 67,000 shares traded. The stock had previously closed at C$0.02.
Quest PharmaTech Price Performance
The firm has a fifty day moving average of C$0.02 and a 200-day moving average of C$0.03. The company has a quick ratio of 0.52, a current ratio of 0.40 and a debt-to-equity ratio of 4.35. The firm has a market cap of C$3.38 million, a P/E ratio of 0.68 and a beta of -0.61.
Quest PharmaTech Company Profile
Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class.
See Also
- Five stocks we like better than Quest PharmaTech
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Quest PharmaTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest PharmaTech and related companies with MarketBeat.com's FREE daily email newsletter.
